Martin Zenker

Has grant

Full professor, head of department

University Hospital Magdeburg
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Identification of novel causative genes for neuro-cardio-facio-cutaneous syndromes by whole exome sequencing and functional analysis of pathogenic mutations

Open Date: 2014-01-01

Close Date: 2018-12-31

Grant: Close

Synaptische Plastizität: Entwicklung und Entwicklungsstörungen

Open Date: 2010-01-01

Close Date: 2015-12-31

Grant: Close

Molecular elucidation of syndromic disorders with congenital or infantile nephrosis (A19)

Open Date: 2008-01-01

Close Date: 2010-12-31

Grant: Close

Genetic determinants of flexibility and specificity in human motivated learning and memory (A08+)

Open Date: 2008-01-01

Close Date: 2016-12-31

Grant: Close

Identifizierung und Charakterisierung neuer Mutationen im Ras Signalweg bei Noonan-Syndrom und juveniler myelomonozytärer Leukämie

Open Date: 2007-01-01

Close Date: 2011-12-31

Articles (3)

The high relevance of childhood trauma in the etiology of borderline personality disorder (BPD) is likely due to epigenetic adaptations associated with exhaustive stress early in life. There is increasing evidence that imbalances in the endogenous opioid system (EOS), which is tightly linked to the stress system, underlie part of the BPD pathophysiology.The aim of this study was to first investigate DNA methylation differences in the promoter regions of the opioid receptor (OR) genes OPRM1 , OPRD1 , and OPRL1 in subjects with BPD (N = 47) and in healthy controls (N = 48). Analyzing individual CG nucleotides (N = 1233), we identified differentially methylated CG sites in OPRM1 (N = 3), OPRD1 (N = 4), and OPRL1 (N = 15). Our findings indicate an increased transcription of these less methylated genes.Further, to study the OR system in its entirety, we analyzed the methylation rate correlation of the CG sites identified to have been differentially methylated in OPRM1 , OPRD1 , and OPRL1 , including existing data of OPRK1 . Distinct associations of the methylation rates were found to form intragenic and intergenic methylation clusters, indicating the impact of methylation alterations on the OR system, and the concurrent activation and mutual regulation of ORs.Together, our findings suggest altered transcription of all OR genes, which likely leads to EOS hypersensitivity and dysregulation, resulting in an unbalanced hyperactivation of inhibitory and disinhibitory effects that may account for the core BPD symptoms. In addition, the observed BPD-related methylation changes in OR genes and their partial synchronization support the role of the EOS in BPD pathobiology.

Year:

2025

Purpose: To determine the cancer risk and spectrum in patients with multilineage mosaic RASopathies with pathogenic variants (PV) in HRAS or KRAS . Experimental Design: We conducted a systematic literature review to identify multilineage mosaic RASopathy cases with a PV in HRAS or KRAS to create a retrospective cohort. We calculated cumulative incidence, cancer-free survival, and hazard rates for cancer and standardized incidence rates (SIR). Results: This study identified 69 patients. Of these, 17% had cancer, including rhabdomyosarcoma (RMS) located in the urogenital region ( n = 7), skin cancer ( n = 3), Wilms tumor ( n = 1), and bladder cancer ( n = 1). Cumulative cancer incidence by age 20 was 20% (95% confidence interval, 4%–37%). The annual cancer hazard rate peaked at 14% within the first 2 years of life. The highest SIR was found for RMS (SIR = 800; 95% confidence interval, 300–1648). Conclusions: This is the first investigation of cancer risk in KRAS or HRAS PV–positive mosaic RASopathies to date. The high incidence and SIR values found highlight the need for rigorous RMS surveillance in young children and skin cancer surveillance in adults with this high-risk condition.

Year:

2024

Year:

2022

Collaborators (3)

Denny Schanze

Institute of Human Genetics

GERMANY
View details

Douglas Stewart

National Institutes of Health

UNITED STATES
View details

Philip Rosenberg

Principal Investigator

National Cancer Institute

UNITED STATES
View details